RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $300
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi maintains an Outperform rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and raises the price target from $265 to $300.
August 02, 2024 | 7:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Luca Issi maintains an Outperform rating on Alnylam Pharmaceuticals and raises the price target from $265 to $300.
The raised price target and maintained Outperform rating from a reputable analyst at RBC Capital is likely to positively impact Alnylam Pharmaceuticals' stock price in the short term. Investors often react favorably to such updates, especially when the price target is significantly increased.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100